专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20020197370A1 Deterioration preventive agent for milk-containing foods 失效
标题翻译：含乳食品的防腐剂
公开(公告)号：US20020197370A1
公开(公告)日：2002-12-26
申请号：US10096832
申请日：2002-03-14
申请人： TAKASAGO INTERNATIONAL CORPORATION
发明人： Tadahiro Hiramoto , Kenji Saiki , Nobutada Kaneko , Yoshihiko Maruta , Kazumasa Sakamoto
IPC分类号： A23B004/00
CPC分类号： A23G3/36 , A01N43/16 , A01N65/08 , A01N65/22 , A23G3/346 , A23G3/368 , A23G3/48 , A23G4/06 , A23G4/068 , A23G4/126 , A23G2200/00 , A23G2200/04 , A23G2200/14 , A23L2/44 , A23L3/3472 , A61K36/535 , A61K36/63 , A61K36/77 , A61K2300/00
摘要： Disclosed are a deterioration preventive agent for milk-containing foods containing as its active ingredient a coumarin analog represented by the general formula (1) below, a glycoside of that analog, or a plant extract containing the coumarin analog or its glycoside: 1 (wherein R1 represents a hydrogen atom, a hydroxyl group or a methoxy group, R2 represents a hydrogen atom or a hydroxyl group, and R1 and R2 are not both hydrogen atoms). The deterioration preventive agent according to the present invention demonstrates superior deterioration preventive effects for milk-containing foods. In addition, the deterioration preventive agent provided by the present invention is friendly to the environment and people.
摘要翻译：公开了含有下列通式（1）表示的香豆素类似物，该类似物的糖苷或含有香豆素类似物或其糖苷的植物提取物作为活性成分的含乳食品的劣化防止剂：（其中R1 表示氢原子，羟基或甲氧基，R2表示氢原子或羟基，R1和R2不同时为氢原子）。根据本发明的防变质剂对含乳食品表现出优异的劣化防止效果。此外，本发明提供的防变质剂对环境和人们都是友好的。

72. 发明授权

US06458384B2 Pharmaceutical with predetermined activity profile 有权
标题翻译：具有预定活动特征的药物
公开(公告)号：US06458384B2
公开(公告)日：2002-10-01
申请号：US09790582
申请日：2001-02-23
申请人： Christof Jaenicke , Jörg Grünwald , Benedikt Hänggi
发明人： Christof Jaenicke , Jörg Grünwald , Benedikt Hänggi
IPC分类号： A61K922
CPC分类号： A61K45/06 , A61K36/77 , A61K36/84 , A61K2300/00
摘要： A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D.1), FIG. 1, and generates a first activity profile (I.1) that has flank phases with increasing and decreasing activity intensity. For changing such flank phases, an additional pharmacologically active substance is used which acts on the same biological function and which is released according to a release profile (D.2) such that its activity profile (I.2) overlays the first activity profile (I.1) within the flank phase to be changed. For shortening an end flank phase, an additional substance is used whose activity is counter to the activity of the first substance and cancels, reduces, or overpowers this activity in its declining phase. Accordingly, with the aforementioned pharmaceutical, undesirable aftereffects of a pharmacologically active substance, for example, can be prevented. In one embodiment, a sedative is contained as a first pharmacologically active substance, which is released immediately, and a stimulant, which is released with delay and thus counteracts uncomfortable aftereffects of the sedative in its end phase, is contained as an additional pharmacologically active substance.
摘要翻译：根据预定的释放曲线（D.1）释放药物中包含的作用于特定生物学功能的第一药理学活性物质， 1，并产生具有增加和减少的活动强度的侧面相位的第一活动谱（I.1）。为了改变这种侧翼相，使用另外的药理活性物质，其作用于相同的生物学功能，并且根据释放特征（D.2）释放，使得其活性谱（I.2）覆盖第一活性谱（ I.1）在改变的侧面阶段。为了缩短端面相，使用其活性与第一种物质的活性相抵消的另外的物质，并在其下降阶段消除，减少或超过该活性。因此，通过上述药物，可以防止例如药理活性物质的不期望的后果。在一个实施方案中，镇静剂作为第一药物活性物质被包含，其立即释放，并且随着释放并因此抵消其终末期的镇静剂的不舒服的后果而产生的兴奋剂作为附加的药理活性物质。

73. 发明申请

US20020055620A1 Reduction inhibitory agent for active oxygen eliminating activity 审中-公开
标题翻译：还原抑制剂用于活性氧消除活性
公开(公告)号：US20020055620A1
公开(公告)日：2002-05-09
申请号：US09984392
申请日：2001-10-30
申请人： KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO
发明人： Hajime Aga , Takashi Shibuya , Shigeharu Fukuda , Toshio Miyake
IPC分类号： C07G003/00 , A01N043/04
CPC分类号： A61K31/7016 , A61K36/03 , A61K36/07 , A61K36/11 , A61K36/15 , A61K36/16 , A61K36/185 , A61K36/21 , A61K36/23 , A61K36/232 , A61K36/27 , A61K36/28 , A61K36/282 , A61K36/287 , A61K36/31 , A61K36/315 , A61K36/42 , A61K36/45 , A61K36/46 , A61K36/48 , A61K36/482 , A61K36/484 , A61K36/515 , A61K36/52 , A61K36/53 , A61K36/534 , A61K36/535 , A61K36/67 , A61K36/68 , A61K36/70 , A61K36/73 , A61K36/734 , A61K36/736 , A61K36/75 , A61K36/752 , A61K36/77 , A61K36/81 , A61K36/82 , A61K36/87 , A61K36/88 , A61K36/886 , A61K36/888 , A61K36/8945 , A61K36/8962 , A61K36/899 , A61K36/8994 , A61K36/8998 , A61K36/9066 , A61K36/9068 , A61K2300/00
摘要： A reduction inhibitory agent for active oxygen eliminating activity comprises trehalose as an active ingredient. This agent can be incorporated into plant edible products and/or plant antioxidants.
摘要翻译：活性氧消除活性的还原抑制剂包括海藻糖作为活性成分。该药剂可以并入植物性食品和/或植物抗氧化剂中。

74. 发明授权

US5795573A Homeopathic pharmaceutical compositions 失效
标题翻译：顺势疗法药物组合物
公开(公告)号：US5795573A
公开(公告)日：1998-08-18
申请号：US004573
申请日：1998-01-08
申请人： Lou Paradise
发明人： Lou Paradise
IPC分类号： A01N65/00 , A61K33/44 , A61K35/00 , A61K36/22 , A61K36/28 , A61K36/77 , A61K36/81
CPC分类号： A61K36/77 , A61K36/22 , A61K36/28 , A61K36/81 , Y10S424/13
摘要： A homeopathic topical anti-inflammatory and pain relieving composition containing an effective amount of the combination of Arnica Montana, Rhus toxicodendron and Aesculus hippocastanum together with belladonna in the form of a lotion, cream or gel.
摘要翻译：一种顺势疗法的局部抗炎和止痛组合物，其含有有效量的山金缕梅，Rhus poisonodendron和七叶树海马的组合以及洗剂，霜剂或凝胶形式的颠茄。

75. 发明授权

US4925870A Therapeutic use of proanthocyanidine A2 as a cytoprotective agent 失效
标题翻译：原花青素A2作为细胞保护剂的治疗用途
公开(公告)号：US4925870A
公开(公告)日：1990-05-15
申请号：US356895
申请日：1989-05-25
申请人： Bruno Gabetta , Maria J. Magistretti , Philippe Dostert
发明人： Bruno Gabetta , Maria J. Magistretti , Philippe Dostert
IPC分类号： A61K31/35 , A61P1/04 , A61P3/06 , A61P9/14 , A61P43/00 , C07D493/18
CPC分类号： C07D493/18 , A61K31/35 , A61K36/77 , A61K9/4858 , A61K2236/00 , A61K9/0014 , A61K9/0019 , A61K9/0056 , Y10S514/926 , Y10S514/927
摘要： There is described a process for preparing proanthocyanidine A2 by extraction from cortex or fruits of Aesculus hippocastanum and related species and its activity for stimulating healing processes, e.g. healing wounds and injuries of various origins, gastric and duodenal ulcers for modifying conditions of impaired capillary permeability and resistance and for obtaining an anti-lipid peroxidation effect.There are also described pharmaceutical formulations suitable for use by topical and systemic routes.

76. 发明授权

US4612194A Anti-rheumatic agents and their use 失效
标题翻译：抗风湿剂及其用途
公开(公告)号：US4612194A
公开(公告)日：1986-09-16
申请号：US700462
申请日：1985-02-11
申请人： Roshdy Ismail
发明人： Roshdy Ismail
IPC分类号： A61K9/48 , A61K31/355 , A61K31/455 , A61K31/48 , A61K36/16 , A61K36/77 , A61K47/10 , A61K31/05 , A61K31/135 , A61K31/35 , A61K31/41 , A61K31/435 , A61K31/44 , A61K31/495 , A61K31/505 , A61K31/52 , A61K35/78
CPC分类号： A61K47/10 , A61K31/355 , A61K31/455 , A61K31/48 , A61K31/685 , A61K36/16 , A61K36/77 , A61K9/4858
摘要： Anti-rheumatic agents contain vitamin E in combination with vasodilators and/or blood circulation-promoting agents. A method of treating rheumatic diseases is disclosed also.
摘要翻译：抗风湿剂含维生素E与血管扩张剂和/或血液循环促进剂的组合。还公开了治疗风湿性疾病的方法。

77. 发明授权

US3170916A Method of producing durable saponine containing extracts from horse chestnut and products obtained therefrom 失效
标题翻译：生产含有栗子的持久皂苷提取物及由其获得的产品的方法
公开(公告)号：US3170916A
公开(公告)日：1965-02-23
申请号：US17430062
申请日：1962-02-19
申请人： CHEM FAB TEMPELHOF PREUSS & TE
发明人： KURT DZIENGEL
IPC分类号： A61K8/97 , A61K36/00 , A61K36/77 , A61Q19/00 , A61Q19/10 , C07H15/256
CPC分类号： A61K8/97 , A61K36/77 , A61Q19/00 , A61Q19/10

78. 发明公开

US20240285721A1 COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF 审中-公开
公开(公告)号：US20240285721A1
公开(公告)日：2024-08-29
申请号：US18659701
申请日：2024-05-09
申请人： HAUS BIOCEUTICALS, INC.
发明人： Tomy YESUDAS , Philip ALEX , Michael CENTOLA , Adam Joshua PAYNE
IPC分类号： A61K36/90 , A61K36/185 , A61K36/22 , A61K36/23 , A61K36/24 , A61K36/27 , A61K36/28 , A61K36/29 , A61K36/31 , A61K36/35 , A61K36/48 , A61K36/66 , A61K36/68 , A61K36/71 , A61K36/76 , A61K36/77 , A61K36/808 , A61K36/899
CPC分类号： A61K36/90 , A61K36/185 , A61K36/22 , A61K36/23 , A61K36/24 , A61K36/27 , A61K36/28 , A61K36/29 , A61K36/31 , A61K36/35 , A61K36/48 , A61K36/66 , A61K36/68 , A61K36/71 , A61K36/76 , A61K36/77 , A61K36/808 , A61K36/899
摘要： Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

79. 发明公开

US20240269107A1 Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines. 审中-公开
公开(公告)号：US20240269107A1
公开(公告)日：2024-08-15
申请号：US18616089
申请日：2024-03-25
申请人： David Alan Heldreth, JR.
发明人： David Alan Heldreth, JR.
IPC分类号： A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC分类号： A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
摘要： The invention involves the use of formulations of positive, negative or other allosteric modulators of primarily 5ht2a receptors, but also those of: 5ht1a/b/c/d, 5ht2b/c, 5ht3, 5ht4, 5ht7, and other receptors in combination with phenethylamines and other compounds; to treat brain cancer such as glioma(s) and/or glioblastoma(s).

80. 发明公开

US20240261252A1 Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. 审中-公开
公开(公告)号：US20240261252A1
公开(公告)日：2024-08-08
申请号：US18581790
申请日：2024-02-20
申请人： David Alan Heldreth, JR.
发明人： David Alan Heldreth, JR.
IPC分类号： A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
CPC分类号： A61K31/352 , A61K31/015 , A61K31/05 , A61K31/135 , A61K31/164 , A61K31/165 , A61K31/404 , A61K31/4045 , A61K31/473 , A61K31/4741 , A61K31/48 , A61K31/675 , A61K31/704 , A61K33/06 , A61K33/30 , A61K36/68 , A61K36/77
摘要： The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazolinel receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式